REFRACTORY MALIGNANT SOLID NEOPLASM
Clinical trials for REFRACTORY MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat cancers: experimental drug aims to boost chemo power
Disease control OngoingThis study is testing a new oral drug called TRC102 (methoxyamine) to see if it can make standard chemotherapy drugs more effective against advanced solid tumors and mesothelioma. It aims to find the safest dose and see if the combination can shrink tumors in patients whose cance…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Targeted drug trial offers hope for Tough-to-Treat cancers with rare mutations
Disease control OngoingThis study is testing whether the drug vismodegib can help control advanced cancers that have specific genetic mutations and have stopped responding to standard treatments. The trial includes 35 adults with solid tumors, lymphoma, or multiple myeloma that have spread or are resis…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Targeted drug trial aims to block Cancer's growth signal
Disease control OngoingThis study is testing whether a pill called crizotinib can help control advanced cancers that have stopped responding to other treatments. It is specifically for patients whose tumors have a particular change in a gene called MET. Participants take the pill twice daily to see if …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial targets Cancer's genetic weakness
Disease control OngoingThis study is testing whether a drug called copanlisib can help control advanced cancers that have stopped responding to other treatments. It is specifically for patients whose cancer has a specific change in a gene called PTEN. The drug is given through an IV and aims to block s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Targeted pill aims to block Cancer's growth signal in Tough-to-Treat tumors
Disease control OngoingThis study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments and have a specific genetic change called a PTEN mutation. The pill is designed to block a protein that these cancer cells may need to gr…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Targeted pill tested for Hard-to-Treat cancers with rare genetic flaws
Disease control OngoingThis study is testing a pill called trametinib for people with advanced cancers that have stopped responding to other treatments and have specific changes in a gene called BRAF. The pill aims to block proteins that these cancer cells need to grow. Researchers want to see if the t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for kids with tough cancers: drug targets unique genetic flaw
Disease control OngoingThis study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug targets Cancer's genetic weakness in Hard-to-Treat cases
Disease control OngoingThis study is testing whether a drug called copanlisib can shrink or stop the growth of advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that cancer cells need to grow. The trial includes 35 adults with various ad…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Early trial tests new drug combo for Tough-to-Treat cancers
Disease control OngoingThis early-stage study aims to find the safest and most effective dose of a new drug, M6620, when given with the chemotherapy drug irinotecan. It is for adults with advanced solid tumors, like certain colorectal, pancreatic, or lung cancers, that have spread or cannot be removed …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Early trial for young cancer patients halted before starting
Disease control TerminatedThis early-phase study aimed to test the safety and effectiveness of a two-drug immunotherapy combination (nivolumab and ipilimumab) in children, teens, and young adults. It was specifically for patients whose cancers had returned or stopped responding to standard treatments and …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
Targeted drug trial offers hope for tough cancers with genetic flaw
Disease control OngoingThis trial is testing whether the drug afatinib can help control advanced cancers that have stopped responding to standard treatments. It is specifically for patients whose tumors have a specific genetic change (mutation) in a gene called EGFR, but who do not have lung cancer. Th…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Targeted pill trial aims to halt growth in Tough-to-Treat cancers
Disease control OngoingThis study is testing if an oral drug called MLN0128 can help control advanced cancers that have a specific genetic change (mTOR mutation) and have stopped responding to other treatments. About 35 patients with various advanced cancers, including solid tumors, lymphoma, or myelom…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Targeted drug tested for tough cancers with specific genetic flaw
Disease control OngoingThis study is testing a drug called trametinib for people with advanced cancers that have a specific genetic change called an NF1 mutation. The drug works by blocking proteins that these cancer cells may need to grow. Researchers want to see if trametinib can shrink these tumors …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Targeted drug trial aims to halt advanced cancers by blocking key growth signal
Disease control OngoingThis study is testing a targeted drug called erdafitinib in patients with advanced cancers that have a specific genetic change (FGFR amplification). The drug works by blocking a faulty protein that tells cancer cells to grow. The trial aims to see if the drug can shrink tumors or…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New combo attack targets Cancer's genetic weakness
Disease control OngoingThis early-phase trial is testing a combination of two drugs, avelumab and M6620, for people with advanced solid tumors that have spread or cannot be removed by surgery. The treatment is specifically for cancers with flaws in certain genes responsible for fixing DNA damage inside…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo tested in Tough-to-Treat cancers
Disease control TerminatedThis early-stage study is testing the safety and best dose of a new two-drug combination (ZEN003694 and binimetinib) for people with advanced solid tumors that have specific genetic changes in the RAS pathway, including triple-negative breast cancer. The trial aims to see if the …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Targeted drug tested for Hard-to-Treat cancers with specific genetic flaw
Disease control OngoingThis study is testing if the drug trametinib can help control advanced cancers that have specific genetic changes called GNAQ or GNA11 mutations. It is for patients with various cancers, including solid tumors and lymphomas, that have not responded to other treatments. The goal i…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Targeted drug trial offers hope for kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing a targeted drug called selpercatinib in children and young adults with advanced or returning cancers that have specific changes in a gene called RET. The goal is to see if the drug can shrink tumors and control the cancer's growth. Participants take the drug…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test new drug duo in fight against tough tumors
Disease control OngoingThis early-stage study is testing the safety and best dose of two drugs, riluzole and sorafenib, when given together. It's for people with advanced solid tumors or melanoma that have spread and are no longer responding to standard treatments. The goal is to see if this combinatio…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Targeted drug tested against Hard-to-Treat cancers with genetic flaw
Disease control OngoingThis study is testing whether the drug palbociclib can shrink or stop the growth of advanced cancers that have specific genetic changes called CCND1, 2, or 3 amplification. The trial includes 40 patients with hard-to-treat solid tumors or lymphomas that have not responded to stan…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Scientists test new drug cocktails for Tough-to-Treat cancers
Disease control OngoingThis early-stage study is testing the safety and best doses of a drug called neratinib when given with one of three other cancer drugs (everolimus, palbociclib, or trametinib). It is for adults with advanced solid tumors that have specific genetic mutations and have stopped respo…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Scientists test new drug duo to starve and stop tough cancers
Disease control OngoingThis early-stage study is testing a combination of two oral drugs, cediranib and selumetinib, in patients with advanced solid tumors that cannot be removed by surgery and have no standard treatment options. The main goals are to find the safest dose and understand the side effect…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug duo aims to block Cancer's growth pathways
Disease control OngoingThis is an early-stage study to find the safest dose of two oral drugs, cabozantinib and pamiparib, when given together. It is for adults with advanced solid tumors that have spread or stopped responding to standard treatments. The goal is to see if blocking multiple cancer growt…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope pill tested for kids with tough cancers
Disease control OngoingThis study is testing whether a pill called cabozantinib can help control rare cancers that have come back or stopped responding to other treatments in children and young adults. It includes patients with sarcomas, Wilms tumor, and other rare tumors. The drug aims to slow or stop…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Targeted drug trial aims to block Cancer's growth signal
Disease control OngoingThis trial is testing whether the drug crizotinib can help control advanced cancers that have a specific genetic change called MET amplification. It is for adults with solid tumors, lymphoma, or multiple myeloma that have stopped responding to other treatments. The drug works by …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Targeted drug trial aims to control tough cancers by hitting their genetic weakness
Disease control OngoingThis study is testing if a drug called MLN0128 can help control advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. It is for adults with solid tumors, lymphoma, or multiple myeloma that …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Targeted drug trial offers new hope for Tough-to-Treat cancers
Disease control OngoingThis study is testing whether a drug called afatinib can help people with advanced cancers that have a specific genetic change called a HER2 mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers are enrolling about 40 patients whose cancers have…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New hope for kids with tough cancers: trial tests precision medicine
Disease control OngoingThis study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Targeted drug trial aims to slow advanced cancers by blocking a faulty gene signal
Disease control OngoingThis study is testing whether the drug sunitinib can help control advanced cancers that have a specific mutation in a gene called cKIT. The drug works by blocking the faulty signal from this mutated gene that tells cancer cells to grow. It is for a small group of patients (about …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New immune therapy cocktail tested in fight against advanced cancers
Disease control OngoingThis study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug combo aims to fight back against resistant cancers
Disease control OngoingThis study is testing whether combining two drugs, nilotinib and paclitaxel, can help control advanced solid cancers that have continued to grow or spread despite previous treatment with a similar class of drugs called taxanes. It is for adults whose disease is getting worse. The…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Drug duo aims to block Cancer's growth signal in Hard-to-Treat tumors
Disease control OngoingThis study is testing whether two drugs, dabrafenib and trametinib, can shrink or stop the growth of advanced cancers that have a specific genetic change called a BRAF V600 mutation. It is for patients with solid tumors, lymphoma, or multiple myeloma that have not responded to ot…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Targeted drug trial aims to block growth signal in tough cancers
Disease control OngoingThis study is testing a drug called defactinib in people with advanced cancers that have stopped responding to other treatments and have a specific genetic change called an NF2 mutation. The drug aims to block a protein that these cancer cells may need to grow. Researchers want t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Cancer trial matches drugs to your Tumor's DNA
Disease control OngoingThis large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New immune attack on rare, aggressive cancers
Disease control OngoingThis study is testing a combination of two immunotherapy drugs, tiragolumab and atezolizumab, for children and adults with rare, aggressive cancers that have come back or stopped responding to standard treatments. These cancers are missing specific genes (SMARCB1 or SMARCA4). The…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Targeted drug trial aims to slow advanced cancers by blocking key mutation
Disease control OngoingThis trial is testing whether the drug osimertinib can help control advanced cancers that have specific changes (mutations) in a gene called EGFR. The drug works by blocking the faulty protein these mutations create, which may slow or stop cancer growth. The study is for adults w…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New hope for kids with tough cancers: treatment guided by tumor genetics
Disease control OngoingThis study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug duo targets genetic weakness in Tough-to-Treat cancers
Disease control OngoingThis study is testing whether two oral drugs, olaparib and ceralasertib (AZD6738), can help control advanced solid tumors that have a specific genetic change called an IDH mutation and have stopped responding to standard therapies. It is for adults with cancers like cholangiocarc…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New drug targets Cancer's genetic weakness
Disease control OngoingThis study is testing an experimental drug called taselisib for people with advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug aims to block a protein that helps cancer cells grow, with the goal of shrinking tumors or stopping their growth. It…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New drug trial targets rare cancer mutations
Disease control OngoingThis trial is testing an oral drug called ulixertinib in patients with advanced cancers that have specific, less common changes in a gene called BRAF. The drug aims to block signals that tell cancer cells to grow, potentially slowing or stopping the disease. It is for patients wi…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:53 UTC
-
New hope for kids with tough cancers: drug targets genetic flaw
Disease control OngoingThis study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Scientists test new drug timing to outsmart resistant cancers
Disease control OngoingThis early-phase study is testing a new way of giving two cancer drugs—one after the other instead of together—to see if it is safe and tolerable for people with advanced solid tumors that have stopped responding to standard treatments. The trial aims to find the best dose and se…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New hope for kids with tough cancers: experimental pill enters trial
Disease control OngoingThis study is testing a new oral drug called Elimusertib in children and young adults whose solid tumors have come back or stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can shrink tumors, particularly in certain types of…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Targeted drug trial aims to block Cancer's growth signal
Disease control OngoingThis study is testing if the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called an ALK rearrangement. It is for people with various solid tumors or blood cancers (excluding certain lung cancers and lymphomas) that have not…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Targeted drug trial aims to block Cancer's growth signal
Disease control OngoingThis study is testing whether the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called a ROS1 translocation. The trial is for patients with various hard-to-treat cancers (like certain solid tumors, lymphomas, or myeloma) tha…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Targeted drug trial offers hope for advanced cancers with specific gene flaw
Disease control OngoingThis study is testing how well the drug palbociclib works for patients with advanced cancers that have not responded to other treatments and have specific changes in their CDK4 or CDK6 genes. The drug aims to block signals that tell cancer cells to grow, potentially slowing or st…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Smart bomb drug trial targets tough cancers with genetic flaw
Disease control OngoingThis trial is testing a targeted drug called ado-trastuzumab emtansine for patients with advanced cancers that have a specific genetic change called HER2 amplification. The drug is designed to find cancer cells with the HER2 marker and deliver chemotherapy directly to them. The s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
New drug targets a key Cancer-Causing mutation
Disease control OngoingThis study is testing a drug called binimetinib in patients with advanced cancers that have a specific genetic change called an NRAS mutation. The drug works by blocking proteins that cancer cells with this mutation need to grow. Researchers want to see if the drug can shrink the…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
New pill targets Cancer's genetic weakness
Disease control OngoingThis trial is testing whether a pill called ipatasertib can help control advanced cancers that have stopped responding to other treatments and have a specific genetic change called an AKT mutation. About 35 patients with various advanced cancers, including solid tumors, lymphoma,…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
New drug duo targets 'Undruggable' cancer mutations
Disease control OngoingThis study is testing the safety and effectiveness of combining two oral drugs, trametinib and navitoclax, for patients with advanced solid tumors that have spread and have specific KRAS or NRAS genetic mutations. The goal is to find the best dose and see if the combination can s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
New targeted therapy trial offers hope for hard-to-treat cancers with specific genetic flaw
Disease control OngoingThis study is testing whether the drug AZD5363 can help control advanced cancers that have a specific genetic change called an AKT mutation. The trial includes 35 patients with various cancers (solid tumors, lymphoma, or myeloma) that have stopped responding to standard treatment…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:24 UTC
-
New drug targets weakness in BRCA cancer cells
Disease control OngoingThis study is testing whether the drug AZD1775 can shrink or stop the growth of advanced cancers that have specific genetic changes called BRCA1 or BRCA2 mutations. The drug works by blocking a protein called WEE1 that these cancer cells may need to survive. The trial will involv…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
Targeted pill tested to control tough cancers with missing protein
Disease control OngoingThis study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments. The drug is specifically for cancers that have completely lost a protein called PTEN. Researchers want to see if the pill can shrink the…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 04, 2026 15:30 UTC
-
Targeted drug trial aims to halt advanced cancers by blocking a key genetic driver
Disease control OngoingThis trial is testing how well the drug larotrectinib works for people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug is designed to block the abnormal protein made by this gene change, which may slow or stop cancer growth. The study is …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 04, 2026 15:29 UTC
-
Cancer experts team up to crack genetic code for better treatments
Knowledge-focused OngoingThis study is testing whether having a team of cancer genetics experts review a patient's tumor test results helps doctors choose more effective treatments. It compares the usual approach where doctors review results alone against having a special 'genomic tumor board' provide ex…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Scientists probe how new cancer drug battles tumors
Knowledge-focused OngoingThis is an early, small study to understand how the drug DS-8201a works in the body of patients with advanced HER2-positive cancers. Researchers are giving the drug to 62 patients and taking small tumor samples before and after treatment to see how it affects cancer cells and the…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC